Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(05): 434-438
DOI: 10.1055/s-0041-1740323
Brief Communication

Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer

Pankaj Wanjarkhedkar 
1   Department of Oncology - VLM Cancer Center; Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India
,
Padmaj Kulkarni 
1   Department of Oncology - VLM Cancer Center; Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India
,
Sachin Hingmire
1   Department of Oncology - VLM Cancer Center; Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India
,
Dhananjay Kelkar
1   Department of Oncology - VLM Cancer Center; Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India
,
Kamlesh Bokil
2   Dwidal Nursing Home, Pune, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Corrected by:

Erratum to: Ayurveda Maintenance Therapy in Recurrent Ovarian CancerIndian J Med Paediatr Oncol 2022; 43(05): e1-e1
DOI: 10.1055/s-0042-1748321

Abstract

Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers relapse. Two cases of recurrent ovarian cancer (ROC) were treated with non–platinum-based Ayurveda maintenance therapy (AMT) consisting of drugs having a herbal and herbomineral origin. This regimen was followed over a period of 3 years and progression-free survival (PFS) was noted along with platinum-free interval (PFI). Two patients were diagnosed with BRCA1 mutated recurrent high-grade serous ovarian carcinoma and treated with the per-oral AMT regimen labeled as ZINCA-30 in our hospital after completion of standard of care treatment and followed up until progression. The ZINCA-30 regimen comprising Jasada (traditional Zinc preparation), Indukanth kwatham and Curcuma amada powder in combination was prescribed based on Rasayana chikitsa postulated in Ayurveda. The patients were followed up every 3 months. The progression-free survival observed in these patients was 28 months and 45 months, respectively. These two pilot cases suggested an increased platinum-free interval (PFI), improved progression-free survival (PFS) in recurrent ovarian cancer (ROC), with the AMT labeled as ZINCA-30 after chemotherapy.

Keywords

recurrent ovarian cancer - progression-free survival - platinum-free interval - ayurveda maintenance treatment - ZINCA-30

Supplementary Material



Publication History

Article published online:
02 February 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References:

  • 1 Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol 2017; 28 (Suppl. 08) viii51 , viii56
    CrossrefPubMedGoogle Scholar
  • 2 Chuang Y-T, Chang C-L. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance. Taiwan J Obstet Gynecol 2012; 51 (03) 336-341
    CrossrefPubMedGoogle Scholar
  • 3 Soyama H, Takano M, Miyamoto M. et al. Factors favouring long-term survival following recurrence in ovarian cancer. Mol Clin Oncol 2017; 7 (01) 42-46
    CrossrefPubMedGoogle Scholar
  • 4 Balachandran P, Govindarajan R. Cancer–an ayurvedic perspective. Pharmacol Res 2005; 51 (01) 19-30
    CrossrefPubMedGoogle Scholar
  • 5 Doshi GM, Une HD, Shanbhag PP. Rasayans and non-rasayans herbs: future immunodrug - Targets. Pharmacogn Rev 2013; 7 (14) 92-96
    CrossrefPubMedGoogle Scholar
  • 6 Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res 2019; 12 (01) 103 DOI: 10.1186/s13048-019-0579-0.
    CrossrefPubMedGoogle Scholar
  • 7 Jorge S, Swisher EM, Norquist BM. et al. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecol Oncol Rep 2019; 29: 113-117
    CrossrefPubMedGoogle Scholar
  • 8 Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res 2014; 7: 57
    CrossrefPubMedGoogle Scholar
  • 9 Du Bois A, Floquet A, Kim J. et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international intergroup trial (AGO-OVAR16). J Clin Oncol 2013; 31 (Suppl. 18) LBA5503-LBA5503
    Google Scholar
  • 10 Pujade-Lauraine E, Ledermann JA, Selle F. et al; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. [published correction appears in Lancet Oncol. 2017 Sep;18(9):e510] Lancet Oncol 2017; 18 (09) 1274-1284
    CrossrefPubMedGoogle Scholar
  • 11 Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 2018; 81 (01) 17-38
    CrossrefPubMedGoogle Scholar
  • 12 Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. Gynecol Oncol 2020; 159 (01) 8-12
    CrossrefPubMedGoogle Scholar
  • 13 Montemorano L, Lightfoot MD, Bixel K. Role of olaparib as maintenance treatment for ovarian cancer: the evidence to date. OncoTargets Ther 2019; 12: 11497-11506
    CrossrefPubMedGoogle Scholar
  • 14 DiSilvestro P, Alvarez Secord A. Maintenance treatment of recurrent ovarian cancer: is it ready for prime time?. Cancer Treat Rev 2018; 69: 53-65
    CrossrefPubMedGoogle Scholar
  • 15 Norquist BM, Harrell MI, Brady MF. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016; 2 (04) 482-490
    CrossrefPubMedGoogle Scholar
  • 16 Tomao F, D'Incalci M, Biagioli E, Peccatori FA, Colombo N. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality?. Cancer 2017; 123 (18) 3450-3459
    CrossrefPubMedGoogle Scholar
  • 17 Jorge S, Swisher EM, Norquist BM. et al. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecol Oncol Rep 2019; 29: 113-117
    CrossrefPubMedGoogle Scholar
  • 18 Vayalil PK, Kuttan G, Kuttan R. Rasayanas: evidence for the concept of prevention of diseases. Am J Chin Med 2002; 30 (01) 155-171
    CrossrefPubMedGoogle Scholar
  • 19 Umrani RD, Paknikar KM. Jasada bhasma, a zinc-based ayurvedic preparation: contemporary evidence of antidiabetic activity inspires development of a nanomedicine. Evid Based Complement Alternat Med 2015; 2015: 193156
    CrossrefPubMedGoogle Scholar
  • 20 Chavare A, Chowdari P, Ghosh S. et al. Safety and bioactivity studies of Jasad Bhasma and its in-process intermediate in Swiss mice. J Ethnopharmacol 2017; 197: 73-86
    CrossrefPubMedGoogle Scholar
  • 21 Pal D, Gurjar VK. (2017) Nanometals in Bhasma: ayurvedic medicine. In: Rai, Ph.D M., Shegokar, Ph.D R., eds. Metal Nanoparticles in Pharma. Springer, Cham. doi-org-443.webvpn.fjmu.edu.cn/10.1007/978-3-319-63790-7_17
    Google Scholar
  • 22 Umrani RD, Paknikar KM. Ayurvedic medicine zinc bhasma: physicochemical evaluation, anti-diabetic activity and safety assessment. J Biomed Nanotechnol 2011; 7 (01) 148-149
    CrossrefPubMedGoogle Scholar
  • 23 Department of AYUSH, Ministry of Health & Family Welfare. The Ayurvedic Formulary of India, Part I. 2nd ed. The Controller of Publications; New Delhi: 2003: 227 , 239
    Google Scholar
  • 24 Bastow M, Kriedt CL, Baldassare J, Shah M, Klein C. Zinc is a potential therapeutic for chemoresistant ovarian cancer. J Exp Ther Oncol 2011; 9 (03) 175-181
    PubMedGoogle Scholar
  • 25 Department of AYUSH, Ministry of Health & Family Welfare. The Ayurvedic Pharmacopeia of India, Part I, Vol V. The Controller of Publications; New Delhi: 2006: 13-15
    Google Scholar
  • 26 Ramachandran C, Lollett IV, Escalon E, Quirin KW, Melnick SJ. Anticancer potential and mechanism of action of mango ginger (Curcuma amada Roxb.) supercritical CO2 extract in human glioblastoma cells. J Evid Based Complementary Altern Med 2015; 20 (02) 109-119
    CrossrefPubMedGoogle Scholar
  • 27 Lin YG, Kunnumakkara AB, Nair A. et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-KB pathway. Clinical Cancer Research 13 (11) 3423-3430
    CrossrefPubMedGoogle Scholar
  • 28 Pandey V. ed. Sahastrayog, Kashaya Prakaran, Chap. 1. Verse 171. CCRAS; New Delhi: 1990: 298
    Google Scholar
  • 29 Savrikar SS, Ravishankar B. Bhaishajya Kalpanaa - the Ayurvedic pharmaceutics - an overview. Afr J Tradit Complement Altern Med 2010; 7 (03) 174-184
    CrossrefPubMedGoogle Scholar
  • 30 Dongre S, Pande S. Need and approach of pharmaceutical standardization of Kwath Kalpana in present scenario-a critique. Int J Ayurveda Pharma Res 2016; 4 (03) 57-60 . Accessed November 26, 2021 at: https://ijapr.in/index.php/ijapr/article/view/321
    Google Scholar
  • 31 Mishra BR, Katre SP. Raktaja Gulma in correlation with modern science conditions. Journal of Ayurveda and Integrated Medical Sciences 2018; 3 (02) 73-77
    Google Scholar
  • 32 George SK, Rajesh R, Kumar S, Sulekha B, Balaram P. A polyherbal ayurvedic drug–Indukantha Ghritha as an adjuvant to cancer chemotherapy via immunomodulation. Immunobiology 2008; 213 (08) 641-649
    CrossrefPubMedGoogle Scholar
  • 33 Sruthi CV, Vendamirtham S, Sindhu A. from the proceedings of Insight Ayurveda 2013, Coimbatore. 24th and 25th May 2013. PA02.20. A comparative study on the total phenolic content and antioxidant property of two Ayurvedic formulations–Indukantham gritham and Indukantham kashayam. Anc Sci Life 2013; 32 (Suppl. 02) S65 DOI: 10.4103/0257-7941.123886.
    CrossrefGoogle Scholar